AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31862004
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 30 mg/kg loading dose and 15 mg/kg/h continuous maintenance infusion for 1 h (group L)
Trial: 22170479
Drug: Apilimod 100
RxNorm normalized name: Apilimod
DrugBank: Apilimod (DB05611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apilimod 100 mg/day for 4 weeks (stage 1)
Trial: 22170479
Drug: Apilimod 100
RxNorm normalized name: Apilimod
DrugBank: Apilimod (DB05611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apilimod 100 mg/day for 8 weeks (stage 2)
Trial: 22170479
Drug: Apilimod 100
RxNorm normalized name: Apilimod
DrugBank: Apilimod (DB05611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apilimod 100 mg twice a day for 8 weeks (stage 3)
Trial: 15725132
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of terminal warm blood cardioplegia (TWBC)
Trial: 15725132
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of terminal warm blood cardioplegia (TWBC)
Trial: 12034651
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 40 mg/d
Trial: 12034651
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 80 mg/d
Trial: 12034651
Drug: Statin-80 (atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin-80 (atorvastatin or simvastatin 80 mg/d)
Trial: 9224205
Drug: Topical fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluticasone propionate (n = 10)
Trial: 8017672
Drug: Propofol (6-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (6-10 mg.kg-1.h-1)
Trial: 29024230
Drug: 0.05 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mol/L GABA
Trial: 29024230
Drug: 0.5 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mol/L GABA
Trial: 18551622
Drug: Arimoclomol at
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arimoclomol at doses up to 300 mg/day
Trial: 18551622
Drug: Arimoclomol at
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arimoclomol at doses of 25, 50, or 100 mg three times daily
Trial: 16075861
Drug: Intramuscular clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular clindamycin (outpatient treatment)
Trial: 16075861
Drug: Intravenous ampicillin/sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin/sulbactam (inpatient treatment)
Trial: 11788637
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg T enanthate
Trial: 11788637
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg T enanthate
Trial: 11788637
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (control)
Trial: 9872813
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 microgram twice daily via Turbohaler)
Trial: 6414252
Drug: Tocainide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (750 mg bolus injection followed by oral therapy)
Trial: 6414252
Drug: Lidocaine (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (conventional therapy)
Trial: 31712584
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg acute dose)
Trial: 24569485
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin (INS)
Trial: 24569485
Drug: Triple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple oral therapy (TOT) with metformin, glyburide, and pioglitazone
Trial: 19013011
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (tamsulosin 0.4 mg and dutasteride 0.5 mg)
Trial: 2499481
Drug: Intravenous SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous SMS 201‐995 (1.7, 0.8, 0.2, and 0.1 micrograms min‐1 for Groups A, B, C, and D respectively)
Trial: 2499481
Drug: Subcutaneous SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous SMS 201‐995 (25 micrograms for Group E)
Trial: 26652184
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide
Trial: 27696012
Drug: Intermittent anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent anticoagulation using NOACs for 48 hours to 1 week based on daily ECG monitoring; patients transmitted daily ECGs using an iPhone-based device.
Trial: 24245553
Drug: Educational course
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational course in skin-protective behaviour and written information about skin care, with access to usual care and treatment.
Trial: 18567877
Drug: 2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg of IVIG over 2 days
Trial: 16484440
Drug: NG-nitro-L-arginine methyl
RxNorm normalized name: NG-nitro-L-arginine methyl ester
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-nitro-L-arginine methyl ester (L-NAME)
Trial: 16484440
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of KETO and L-NAME
Trial: 16484440
Drug: Control site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control site (Ringer solution)
Trial: 16484440
Drug: Local heating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local heating with L-NAME
Trial: 10846252
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate regimen with constant dose
Trial: 10846252
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate regimen with initial loading dose
Trial: 10846252
Drug: Conventional therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapeutic regimen of two capsules daily for three months
Trial: 8257138
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AZT with breakfast (B)
Trial: 8257138
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg AZT with breakfast (B)
Trial: 8257138
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AZT fasting (F)
Trial: 8257138
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg AZT fasting (F)
Trial: 8257138
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AZT breakfast (B)
Trial: 8257138
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg AZT breakfast (B)
Trial: 2931047
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin as two 250‐mg tablets
Trial: 2931047
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin as one 500‐mg tablet
Trial: 2931047
Drug: Ciprofloxacin solution
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin solution
Trial: 27146169
Drug: Insufficient s‐25[OH]D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient s‐25[OH]D <50 nmol/L
Trial: 27146169
Drug: Sufficient s‐25[OH]D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient s‐25[OH]D >80 nmol/L
Trial: 22672713
Drug: External-hexagon implants
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External-hexagon implants with flat-to-flat implant-abutment interface
Trial: 18543158
Drug: Dynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic treatment protocol (passive extension with a rubber band system)
Trial: 18543158
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment protocol (early active extension of the thumb)
Trial: 15967908
Drug: Laparoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Trial: 15967908
Drug: Open surgery
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Trial: 12623838
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg IV on day 1) + IL-2 (0.25 to 3 x 10^6 IU/m2 continuous IV infusion from day 3 to day 8)
Trial: 12623838
Drug: Pamidronate +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate + modified IL-2 (6-hour bolus IV infusions from day 1-6)
Trial: 12623838
Drug: Pamidronate +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate + low-dose IL-2
Trial: 10580431
Drug: CSII plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII plus troglitazone (600 mg/day)
Trial: 10580431
Drug: CSII plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII plus metformin (1,700 mg/day)
Trial: 31142947
Drug: Oral Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Itraconazole for 4 weeks
Trial: 31142947
Drug: Oral Terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Terbinafine for 4 weeks
Trial: 11387364
Drug: 40 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 Gy total fractionated dose for the clinically noninvolved extended field (arm A)
Trial: 11387364
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy total fractionated dose for the clinically noninvolved extended field (arm B)
Trial: 9407458
Drug: cilazapril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (2 mg/day)
Trial: 7714164
Drug: 200 or
RxNorm normalized name: Mag-200 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 or 400 mg RU486 administered on day LH+2
Trial: 7714164
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no RU486 treatment)
Trial: 2967936
Drug: Duovent (fenoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duovent (fenoterol 0.1 mg/ipratropium 0.04 mg per puff)
Trial: 2967936
Drug: Salbutamol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.1 mg per puff)
Trial: 21975318
Drug: Adjuvant HAI‐FUDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant HAI‐FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinotecan
Trial: 21975318
Drug: Modern systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern systemic chemotherapy alone
Trial: 15909609
Drug: Fructose 1.6-diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose 1.6-diphosphate (FDP) administered i.v. for 7 consecutive days
Trial: 2513207
Drug: Standard metrifonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard metrifonate treatment (3 doses of 7.5 mg.kg‐1 at two‐weekly intervals)
Trial: 2513207
Drug: Abbreviated metrifonate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated metrifonate treatment (3 doses of 5 mg.kg‐1 in one day)
Trial: 22898035
Drug: BIIB021 600
RxNorm normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB021 600 mg twice a week (BIW)
Trial: 22898035
Drug: BIIB021 400
RxNorm normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB021 400 mg three times a week (TIW)
Trial: 11527645
Drug: GTN (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN (0.6 mg/h/24 h)
Trial: 11527645
Drug: PETN (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PETN (60 mg orally three times a day)
Trial: 9419950
Drug: UDCA 600
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 600 mg per day
Trial: 2820289
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy (cyclophosphamide, doxorubicin, vincristine alternating with etoposide (100 mg/m2 on days 1 to 3) and cisplatin (25 mg/m2 on days 1 to 3) every 3 weeks for six treatment cycles)
Trial: 2820289
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (cyclophosphamide (1000 mg/m2), doxorubicin (50 mg/m2), and vincristine (2 mg) every 3 weeks for six courses)
Trial: 30374055
Drug: Testing for
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing for immunoglobulin M (IgM) and G (IgG) responses against 20 microbes associated with TBD
Trial: 26799451
Drug: Topical 25%
RxNorm normalized name: urea topical 25% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 25% sodium metabisulfite
Trial: 16034446
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 60 mg
Trial: 14512180
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg/kg/day start, tapering doses)
Trial: 11022398
Drug: Tryptophan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (2 to 4 g per day) with fluoxetine (20 mg per day)
Trial: 11022398
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with fluoxetine (20 mg per day)
Trial: 1321490
Drug: 1:200,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:200,000 epinephrine in a four percent articaine‐HCl solution
Trial: 1321490
Drug: 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:100,000 epinephrine in a four percent articaine‐HCl solution
Trial: 6514177
Drug: Pirlindole with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirlindole with ethanol (0.4 g 17 vol%/kg)
Trial: 24551029
Drug: Prophylactic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low dose penicillin V (6 months for first episode, 12 months for recurrent cellulitis)
Trial: 24551029
Drug: Prophylactic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low dose penicillin V
Trial: 20118492
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg once daily
Trial: 20118492
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (PEG-IFN-alpha 2b and ribavirin)
Trial: 15642859
Drug: Prednisone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.75 mg/kg daily for the first 10 days of each month for 6 months)
Trial: 15642859
Drug: Placebo (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.75 mg/kg daily for the first 10 days of each month for 6 months)
Trial: 8384278
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg Lomefloxacin (200 mg b.i.d.)
Trial: 8384278
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Lomefloxacin (200 mg t.i.d.)
Trial: 25193943
Drug: No-pain control
RxNorm normalized name: Biochemistry Heel No Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-pain control treatment
Trial: 20613472
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 microg/ml)
Trial: 19024258
Drug: Implant brushing
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant brushing on machined surfaces
Trial: 12647006
Drug: Intratunical instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratunical instillation of 2.5 mL of 0.5 % bupivacaine combined with 10 mg/ml methylprednisolone
Trial: 12647006
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only analgesics postoperatively by intramuscular route
Trial: 11004352
Drug: Ethyl icosapentate
RxNorm normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ethyl icosapentate 1800 mg daily and estriol (E3) 2 mg daily (eicosapentaenoic acid group, n = 69)
Trial: 11004352
Drug: Estriol (E3)
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol (E3) 2 mg daily (control group, n = 72)
Trial: 8976475
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) combined with trunk strengthening exercises (TSE)
Trial: 8976475
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) combined with trunk stretching exercises
Trial: 8976475
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug (NSAID) therapy combined with trunk strengthening exercises (TSE)
Trial: 1361797
Drug: Neomycin sulphate
RxNorm normalized name: Neomycin sulphate
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin sulphate nasal ointment
Trial: 24253788
Drug: Actifuse combined
RxNorm normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actifuse combined with 5 mL of bone marrow aspirate (n = 26)
Trial: 24253788
Drug: rhBMP-2 (4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP-2 (4.2 mg, n = 26)
Trial: 20823643
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg per day)
Trial: 20823643
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg per day)
Trial: 20823643
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg per day) in obese subjects
Trial: 15691639
Drug: HDFU (5FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDFU (5FU 3 g/m2 intravenously, 24 h infusion, weekly for 6 weeks)
Trial: 15691639
Drug: 5FU+FA+CDDP (5FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU+FA+CDDP (5FU 2.0 g/m2 i.v. with folinic acid 500 mg/m2, 2 h-infusion, weekly for 6 weeks + cisplatin 50 mg/m2, once every two weeks for 6 weeks)
Trial: 10376776
Drug: Zinc (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (70 mg, once per week)
Trial: 10376776
Drug: Zinc and
RxNorm normalized name: Zinc and/or zinc compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc and Vitamin A (70 mg Zn and 3030 RE vitamin A, once per week)
Trial: 30515970
Drug: adalimumab (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab (TNF inhibitor)
Trial: 30515970
Drug: ustekinumab (IL-12/23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ustekinumab (IL-12/23 inhibitor)
Trial: 30342645
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine injection (7.5% ropivacaine, 10 mL total, 5 mL each into both uterosacral ligaments)
Trial: 30342645
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (10 mL total, 5 mL each into both uterosacral ligaments)
Trial: 10710805
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose and 0.075% lidocaine in bacteriostatic water (active solution)
Trial: 10710805
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution absent 10% dextrose
Trial: 26630718
Drug: Red Cross
RxNorm normalized name: Cotton Red Cross 2oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Cross Canker Sore Medication
Trial: 1490488
Drug: Droxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxicam (20 mg single dose)
Trial: 1490488
Drug: Droxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxicam (20 mg/day for 30 consecutive days)
Trial: 1490488
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg single dose)
Trial: 1490488
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg/day for 30 consecutive days)